Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Sulfur – selenium or tellurium compound
Reexamination Certificate
2007-02-27
2007-02-27
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Sulfur, selenium or tellurium compound
C568S075000, C568S077000, C549S058000, C514S443000
Reexamination Certificate
active
10997039
ABSTRACT:
Disclosed herein are compounds comprisingor a pharmaceutically acceptable salt or a prodrug thereof;wherein Y, A, B, J, and E are further described.Methods, compositions, and medicaments related thereto are also disclosed.
REFERENCES:
patent: 4131738 (1978-12-01), Smith
patent: 4147877 (1979-04-01), Smith
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 6043275 (2000-03-01), Maruyama et al.
patent: 6410591 (2002-06-01), Burk et al.
patent: 6538018 (2003-03-01), Burk et al.
patent: 6552067 (2003-04-01), Cameron et al.
patent: 6586468 (2003-07-01), Maruyama et al.
patent: 7101906 (2006-09-01), Donde et al.
patent: 1601994 (1981-11-01), None
patent: WO 02/102389 (2002-12-01), None
Carey, Francis A., Organic Chemistry, New York: McGraw-Hill Book Company 1987, p. 63.
Chourasia, M.K., and Jain, S.K.Pharmaceutical approaches to colon targeted drug delivery systems, J Pharm Pharmaceut Sci 6 (1): 33-66, 2003.
Kabashima, K. et. al.,The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut, The Journal of Clinical Investigation, Apr. 2002, vol. 9, 883-893.
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 16th Edition, 1980.
Shareef, M.A., et. alColonic Drug Delivery: an Updated Review, AAPS PharmSci 2003; 5 (2) Article 17.
Burk Robert M.
Donde Yariv
Garst Michael E.
Holoboski Mark
Posner Mari F.
Allergan Inc.
Baran Robert J.
Johnson Brent A.
Lambkin Deborah C.
Voet Martin A.
LandOfFree
2,3,4-substituted cyclopentanones as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,3,4-substituted cyclopentanones as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,3,4-substituted cyclopentanones as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3887241